GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19034284 | Stomach | WIM | positive regulation of reactive oxygen species biosynthetic process | 4/426 | 24/18723 | 1.96e-03 | 2.41e-02 | 4 |
GO:00321031 | Stomach | WIM | positive regulation of response to external stimulus | 20/426 | 427/18723 | 1.96e-03 | 2.41e-02 | 20 |
GO:20012364 | Stomach | WIM | regulation of extrinsic apoptotic signaling pathway | 10/426 | 151/18723 | 2.43e-03 | 2.84e-02 | 10 |
GO:004573241 | Stomach | WIM | positive regulation of protein catabolic process | 13/426 | 231/18723 | 2.53e-03 | 2.92e-02 | 13 |
GO:00725951 | Stomach | WIM | maintenance of protein localization in organelle | 5/426 | 42/18723 | 2.53e-03 | 2.92e-02 | 5 |
GO:00327571 | Stomach | WIM | positive regulation of interleukin-8 production | 6/426 | 62/18723 | 2.81e-03 | 3.11e-02 | 6 |
GO:01100964 | Stomach | WIM | cellular response to aldehyde | 3/426 | 13/18723 | 2.82e-03 | 3.11e-02 | 3 |
GO:190336441 | Stomach | WIM | positive regulation of cellular protein catabolic process | 10/426 | 155/18723 | 2.94e-03 | 3.16e-02 | 10 |
GO:190121511 | Stomach | WIM | negative regulation of neuron death | 12/426 | 208/18723 | 2.99e-03 | 3.19e-02 | 12 |
GO:00700594 | Stomach | WIM | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 6/426 | 63/18723 | 3.05e-03 | 3.24e-02 | 6 |
GO:1902883 | Stomach | WIM | negative regulation of response to oxidative stress | 4/426 | 27/18723 | 3.06e-03 | 3.24e-02 | 4 |
GO:190260041 | Stomach | WIM | proton transmembrane transport | 10/426 | 157/18723 | 3.23e-03 | 3.35e-02 | 10 |
GO:19034093 | Stomach | WIM | reactive oxygen species biosynthetic process | 6/426 | 64/18723 | 3.30e-03 | 3.41e-02 | 6 |
GO:20001174 | Stomach | WIM | negative regulation of cysteine-type endopeptidase activity | 7/426 | 86/18723 | 3.45e-03 | 3.54e-02 | 7 |
GO:000646941 | Stomach | WIM | negative regulation of protein kinase activity | 12/426 | 212/18723 | 3.48e-03 | 3.55e-02 | 12 |
GO:003243441 | Stomach | WIM | regulation of proteasomal ubiquitin-dependent protein catabolic process | 9/426 | 134/18723 | 3.59e-03 | 3.60e-02 | 9 |
GO:003295641 | Stomach | WIM | regulation of actin cytoskeleton organization | 17/426 | 358/18723 | 3.62e-03 | 3.60e-02 | 17 |
GO:003133141 | Stomach | WIM | positive regulation of cellular catabolic process | 19/426 | 427/18723 | 4.39e-03 | 4.12e-02 | 19 |
GO:190382921 | Stomach | WIM | positive regulation of cellular protein localization | 14/426 | 276/18723 | 4.49e-03 | 4.16e-02 | 14 |
GO:004682531 | Stomach | WIM | regulation of protein export from nucleus | 4/426 | 30/18723 | 4.53e-03 | 4.16e-02 | 4 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |